Effects of Biologics on the Nasal Bacterial Environment in Patients with Nasal Polyps

Study on the Regulatory Effects and Causal Mechanisms of Targeted Biologics on the Nasal Microbiota in Patients with Chronic Rhinosinusitis with Nasal Polyps.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600131196

Enrollment

Unknown

Registered

2026-08-31

Start date

2026-09-01

Completion date

Unknown

Last updated

2026-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CRSwNP

Interventions

Experimental group:None

Disease control group:None

Healthy control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with CRS and CRSwNP in accordance with the EPOS 2020 guidelines, confirmed by medical history, clinical examination, nasal endoscopy, and computed tomography (CT), and who concurrently satisfy the Chinese eligibility criteria for biologic therapy in chronic rhinosinusitis with nasal polyps.

Exclusion criteria

Exclusion criteria: 1.Patients were excluded if they met any of the following criteria: age < 18 years; 2.pregnancy; 3.malignancy; 4.immune disorders; 5.use of antibiotics or systemic/topical intranasal corticosteroids within 4 weeks prior to enrollment; 6.or a history of cystic fibrosis, immunocompromised conditions, autoimmune diseases, or primary mucociliary dysfunction.

Design outcomes

Primary

Measure	Time frame
Nasal microbiota Shannon diversity index;	—

Secondary

Measure	Time frame
SNOT-22 score;Blood Immuno-inflammatory Indicators;VAS (Visual Analogue Scale) score;	—

Countries

China

Contacts

Public ContactLiu Feng

West China Hospital of Sichuan University

entliufeng@wchscu.edu.cn+86 18980606340

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026